Publication

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

Journal Paper/Review - Feb 8, 2023

Units
PubMed
Doi
Contact

Citation
Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance J, González-Del-Alba A, Delgado M, Nolè F, Turco F, Mestre R, Ribi K, Cathomas R. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). J Clin Oncol 2023; 41:3608-3615.
Type
Journal Paper/Review (English)
Journal
J Clin Oncol 2023; 41
Publication Date
Feb 8, 2023
Issn Electronic
1527-7755
Pages
3608-3615
Brief description/objective

To assess the efficacy and safety of darolutamide maintenance after successful taxane chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).